Exact Sciences Nets $64.7M from Stock Offering

Exact Sciences will use the funds to support clinical trials of its stool-based DNA colorectal cancer screening test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories